Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 CuraGen To Close Pilot Plant | Contract Pharma

What are you searching for?

Sign in
Breaking News

CuraGen To Close Pilot Plant

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

CuraGen Corp. will close its pilot manufacturing plant, effective July 27, 2007. As a result, the company will reduce its workforce by approximately 40 employees, primarily composed of preclinical and manufacturing researchers, and additional support staff from within the organization. CuraGen previously announced that it would make reductions in early-stage and preclinical drug discovery and decreased emphasis on internal manufacturing capabilities.

The pilot facility, also known as the Biopharmaceutical Sciences Process (BPS) facility, is a 29,000-sq.-ft. leased facility that was used by CuraGen for pilot scale production of proteins and antibodies. The BPS facility primarily supported early-stage pipeline development and non-GMP manufacturing.

Affected employees will be eligible for a severance package that includes severance pay, continuation of benefits and outplacement services. Charges relating to this move, the majority of which will be accrued during the second quarter of 2007, are estimated to be approximately $8 million, including non-cash charges of approximately $6 million in writeoffs.

“The contribution made by all members of the CuraGen team is sincerely and deeply appreciated. This strategic decision was difficult but necessary to ensure that CuraGen focuses its resources and invests appropriately into velafermin, belinostat and CR011-vcMMAE which represent the most significant value to CuraGen, its employees and its shareholders,” stated Frank Armstrong, M.D., president and chief executive officer of CuraGen.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics